SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?

Lancet Gastroenterol Hepatol. 2021 Jul;6(7):528-529. doi: 10.1016/S2468-1253(21)00184-9. Epub 2021 May 26.

Authors

James L Alexander¹, Nick Powell²; British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group

Affiliations

¹ Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK.
² Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK; Department of Gastroenterology, Imperial College Healthcare NHS Trust, London, UK. Electronic address: nicholas.powell@imperial.ac.uk.

No abstract available

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Gastroenterology*
Humans
Inflammatory Bowel Diseases* / drug therapy
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines

Grants and funding

MC_PC_14105/MRC_/Medical Research Council/United Kingdom